Belluscura Overview
- Founded
-
2015
- Status
-
Public
- Employees
-
9
- Stock Symbol
-
BELL
- Investments
-
2
- Share Price
-
$1.04
- (As of Thursday Closing)
Belluscura General Information
Description
Belluscura PLC is a medical device company. Its first product, the X-PLOR, is a lightweight FDA cleared portable oxygen concentrator designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices. The X-PLO2R weighs less than 1.5kg (3.25lbs) and it is the first modular portable oxygen concentrator and that it will generate more oxygen by weight than any other FDA cleared POC in its class. It either owns or exclusively licenses a total of 26 patents and applications relating to oxygen enrichment devices and treatments.
Contact Information
Primary Industry
Therapeutic Devices
Stock Exchange
LON
Primary Office
- 15 Fetter Lane
- London EC4A 1BW
- England, United Kingdom
Belluscura Timeline
Belluscura Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.04 | $1.07 | $0.75 - $2.08 | $126M | 121M | 75.7K | -$0.06 |
Belluscura Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2021 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 149,420 | 149,420 | ||
| Revenue | 420 | 420 | 0 | 129 |
| EBITDA | (4,917) | (4,917) | (1,839) | (1,407) |
| Net Income | (5,213) | (5,213) | (1,978) | (1,552) |
| Total Assets | 26,005 | 26,005 | 5,237 | 4,530 |
| Total Debt | 370 | 370 | 495 | 498 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Belluscura Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Belluscura Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Belluscura Patents
Belluscura Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210196916-A1 | Systems and methods for improving patient health | Pending | 11-Sep-2018 | 00000000000 |
Belluscura Executive Team (6)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Robert Rauker JD | Chief Executive Officer & Board Member | ||
| Anthony Dyer | Chief Financial Officer & Board Member | ||
| Cary Parrott | Vice President of Sales |
Belluscura Board Members (8)
| Name | Representing | Role | Since |
|---|---|---|---|
| Adam Reynolds | Self | Chairman | 000 0000 |
| Anthony Dyer | Belluscura | Chief Financial Officer & Board Member | 000 0000 |
| Patrick Strollo | Self | Board Member | 000 0000 |
| Robert Rauker JD | Belluscura | Chief Executive Officer & Board Member | 000 0000 |
Belluscura Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Belluscura Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Belluscura Acquisitions (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000000 00 | 25-Apr-2017 | 0000000000 | 00000 | Biotechnology | 000000 00 |
| Stryker Corporation (Medical Devices) | 13-Apr-2016 | Merger/Acquisition | Other Commercial Services |